期刊文献+

麦考酚钠肠溶片在肾移植受者初始免疫抑制治疗的观察 被引量:2

下载PDF
导出
摘要 吗替麦考酚酯(MMF)是一种新型抗代谢类免疫抑制剂,通过在体内脱酯转化为麦考酚酸(MPA)活性成分发挥作用。MPA是次黄嘌呤单核苷酸脱氢酶抑制剂,抑制鸟嘌呤核苷酸的从头合成,有效抑制T、B淋巴细胞增殖,而发挥高效的免疫抑制作用。MMF与钙调磷酸酶抑制剂(CNI)联合应用能够显著改善移植物的长期存活。临床已用于预防和治疗肾、肝、心脏及骨髓器官移植的排异反应。麦考酚钠肠溶片(EC-MPS,商品名米芙)是MPA的钠盐形式,疗效与MMF相似,与MMF立即在胃中释放MPA不同,EC-MPS在小肠中延迟释放MPA,明显地提高了患者的依从性和耐受性。现报告如下。
出处 《中国药物与临床》 CAS 2012年第7期935-936,共2页 Chinese Remedies & Clinics
  • 相关文献

参考文献6

  • 1Ams W. Noninfectious gastrointestinal(GI)complications of my- cophenolic acid therapy:a consequence of local GI toxicity. Transplant Proc, 2007,39( 1 ) : 88-93.
  • 2Qureshi A,Scheinfeld N. Myfortic (mycophenolate sodium)de- layed-release tablets. Dermatol Online J,2008,14(8):4.
  • 3Budde K,Tedesco-Silva H,Pestana JM,et al. Enteric-coated my- cophenolate sodium provides higher mycophenolic acid predose- levels compared with mycophenolate mofeil:implications for ther- apeutic drug monitoring. Ther Drug Monit, 2007,29(3) : 381-384.
  • 4Legendre C,Cohen D,Zeier M,et al. Efficacy and safety of en- teric-coated mycophenolate sodium in de novo renals transplant recipients : pooled data from three 12-month muhicenter, open-la- bel,prospective studies. Transplant Proc,2007,39 (5):1386- 1391.
  • 5Salvadori M,Holzer H,de Mattos A,et al. Enteric-coated my- cophenolate sodium is therapeutically equivalent to mycopheno- late mofetil in de novo renal transplant patients. Am J Trans- plant, 2004,4 ( 2 ) : 231-236.
  • 6Bolin P,Tanfiover B,Zibari GB,et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enterieeoated myeophenolate sodium in renal transplant patients.Transplantation, 2007,84 ( 11 ) : 1443- 1451.

同被引文献14

  • 1王成永,时军,王姝婧.奥美拉唑肠溶微丸制备及其质量影响因素探讨[J].安徽医药,2005,9(7):493-493. 被引量:8
  • 2Salvadori M, Benoni E, Budde K, et al. Superior efficacy of enteric-coated mycophenolate VS mycophenolate mofetil in de novo transplant recipients:pooled analysis[J]. Transplant Proc, 2010, 42(4):1325-1328.
  • 3Sollinger HW, Sundberg AK, Leverson G, et al. Mycopheno- late mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and out- comes in kedney transplant recipients[J]. Transplantation, 2010, 89(4):446-451.
  • 4Frei P, Weber A, Geier A, eta/. Lessons from a transplant pa- tient with diarrhea, cryptosporidial infection, and possible mycophenolate mofefil-associated colitis[J]. Transpl Infect Dis, 2011, 13(4):416-418.
  • 5Womard JB, Rerolle JV, Picard N, et aL Risk of diarrhea in a long-term cohort of renal transplant patients given mycophe- nolate mofetihthe significant role of the UGT1A8 2 variant allele[J]. Br J Clin Pharmacol, 2010, 69(6):675"683.
  • 6Gozdowska J, Urbanowicz A, Baczkowska T, et al. Safety and tolerance of sodium mycophenolate in patients after renal transplantation-an observational study[J]. Transplant Proc, 2009, 41(8):3016-3018.
  • 7Bolin P, Tanriover B, Zibari GB, et al. Improvement in 3- month patient-reported gastrointestinal symptoms after con- version from mycophenolate mofetil to entericcoated myeo- phenolate sodium in renal transplant patients[J]. Transplan- tation, 2007, 84(11): 1443-1451.
  • 8Rupprecht K, Schmidt C, Rasp6 A, et al. Bioavailability of myeophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers[J]. J Clin Pharmacol, 2009, 49(10): 1196-1201.
  • 9陆春晓.吗替麦考酚酯胶囊含量和有关物质的测定[J].海峡药学,2010,22(2):48-50. 被引量:1
  • 10张忠伟,陈一凡.吗替麦考酚酯干混悬剂的制备及含量测定[J].药学与临床研究,2011,19(1):85-86. 被引量:5

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部